Glass Label/Claim Audit

Blood Pressure Reduction

Durable audit route for one claim-like target. This page shows source-use records, assessment rationale, active challenges, revisions, and graph edges tied to the same target identity.

1 active challenge1 revisionevidence high
Assessment Rationale

High confidence for blood-pressure reduction in hypertensive or cardiometabolic-risk contexts; moderate expected magnitude.

The evidence rating is high because the claim is supported by direct human blood-pressure endpoints rather than only animal, biomarker, or mechanistic evidence. The direction of effect is coherent with cardiovascular mechanism context, but the claim is intentionally limited to elevated-risk populations where the signal is most defensible.

Magnitude is moderate because the reported systolic and diastolic changes are large enough to matter clinically in elevated-risk users, but they should not be treated as drug-like blood-pressure control or generalized to normotensive users.

Evidence Reviewed

Sources considered for this assessment[1][2]

Claim Scope
Population
Hypertensive Or Cardiometabolic-Risk Adults
Endpoint
Systolic And Diastolic Blood Pressure
Context
Supplemental Taurine Used For Blood-Pressure Endpoints, Not General Cardiovascular Wellness.
Does not mean
  • - Not established for normotensive users
  • - Not equivalent to antihypertensive medication
  • - Not a universal heart-health claim
Basis For Judgment
01DirectnessHigh

The cited support includes human systolic and diastolic blood-pressure endpoints.

02Population fitMedium

Best fit is hypertensive or cardiometabolic-risk users, not the general population.

03ConsistencyMedium

The direction is coherent across endpoint and mechanism support, while dose and baseline status remain important.

04Magnitude confidenceMedium

The effect appears clinically meaningful but not comparable to primary antihypertensive therapy.

Raises confidence
  • - direct human endpoint evidence
  • - mechanistic plausibility through vascular tone and sympathetic context
Limits confidence
  • - population specificity
  • - dose and baseline blood pressure affect interpretation
  • - limited long-term outcome data
Disputable assumptions
  • - blood-pressure endpoint interpretation
Source Use Records

Local evidence attached to this claim

DirectDirect Endpoint EvidenceDirect Human Endpoint5/5 quality fields

Taurine and calcium-handling cardioprotection

Reduces systolic and diastolic blood pressure through modulation of vascular tone and sympathetic activity.

This source is used as direct support for a blood-pressure effect because it addresses systolic/diastolic blood-pressure endpoints rather than a general cardiovascular wellness claim.

Endpoint
Blood Pressure Reduction
Population
Healthy adults or at-risk adults
Dose / Exposure
1-6 g/day oral
Duration
2-12 weeks
Directness
Direct Human Endpoint
DirectDirect Endpoint EvidenceDirect Human Endpoint5/5 quality fields

Effect of taurine on blood pressure: Meta-analysis

The study reports reduced blood pressure after taurine supplementation in a human cardiometabolic population.

This source directly supports the blood-pressure effect, but the claim should remain population-specific rather than universal.

Endpoint
Systolic and diastolic blood pressure
Population
Adults with elevated cardiometabolic or blood-pressure risk
Dose / Exposure
Study-specific oral taurine dosing
Duration
Short-to-medium intervention window
Directness
Direct Human Endpoint